Simvastatin (Zocor) Therapy in Sickle Cell Disease

Completed · Phase 1/Phase 2

Conditions studied: Sickle Cell Disease

In brief

Recent clinical and experimental data indicate that statins have effects beyond cholesterol lowering that may be beneficial in sickle cell disease by protecting the vascular endothelium. Statins have been shown to attenuate endothelial dysfunction through their anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II dose-escalating trial is designed to assess the safety and potential clinical efficacy of oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).

Key facts

Study ID
NCT00508027
Run by
UCSF Benioff Children's Hospital Oakland
People needed
42
Starts
2007-06-01
Expected to finish
2011-12-01
Last updated by the study team
2013-09-17

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.